The PARP inhibitor olaparib was recently evaluated in a phase I clinical trial and showed antitumour activity in BRCA1 or BRCA2 mutation carriers with ovarian, breast or prostate cancer (Fong et al, 2009). Here, BRCA2 is linked to prostate carcinoma.